4572 Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Carna Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥300.00 |
| 52 Week High | JP¥510.00 |
| 52 Week Low | JP¥260.00 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -1.32% |
| 1 Year Change | -31.51% |
| 3 Year Change | -69.82% |
| 5 Year Change | -84.50% |
| Change since IPO | -71.15% |
Recent News & Updates
Recent updates
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Aug 06
What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
Shareholder Returns
| 4572 | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 12.8% | 3.2% | 1.4% |
| 1Y | -31.5% | -11.7% | 7.4% |
Return vs Industry: 4572 underperformed the JP Life Sciences industry which returned -11.7% over the past year.
Return vs Market: 4572 underperformed the JP Market which returned 7.4% over the past year.
Price Volatility
| 4572 volatility | |
|---|---|
| 4572 Average Weekly Movement | 7.4% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4572's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4572's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 67 | Kohichiro Yoshino | www.carnabio.com |
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, and tyrosine kinase cell-based assay services.
Carna Biosciences, Inc. Fundamentals Summary
| 4572 fundamental statistics | |
|---|---|
| Market cap | JP¥5.73b |
| Earnings (TTM) | -JP¥1.51b |
| Revenue (TTM) | JP¥1.40b |
4.1x
P/S Ratio-3.8x
P/E RatioIs 4572 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4572 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.40b |
| Cost of Revenue | JP¥174.52m |
| Gross Profit | JP¥1.23b |
| Other Expenses | JP¥2.74b |
| Earnings | -JP¥1.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 10, 2025
| Earnings per share (EPS) | -79.09 |
| Gross Margin | 87.54% |
| Net Profit Margin | -107.80% |
| Debt/Equity Ratio | 2.2% |
How did 4572 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 22:43 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carna Biosciences, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yen Ting Chen | Credit Suisse |